Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7563)	12/20/2002 12:27:45 PM
From: Vector1	Respond to of 52153

Peter, I agree. The news flow recently has been very good. I wonder why there hasn't been a better reaction. It may be delayed until the new year. V1

To: Biomaven who wrote (7563)	12/20/2002 1:05:08 PM
From: rkrw	Respond to of 52153

Also this one, announced after the close yesterday. This is a 50/50 deal between ENDP and PPCO. Nice reaction today for ppco. Endo Pharmaceuticals Submits New Drug Application For Extended Release Oxymorphone Utilizing Penwest's TIMERx Technology Thursday December 19, 6:19 pm ET - Submission Represents Important Milestone for Penwest PATTERSON, N.Y., Dec. 19 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. (Nasdaq: PPCO - News) announced today that Endo Pharmaceuticals Inc. submitted a New Drug Application (NDA) to the US Food and Drug Administration for oxymorphone extended release tablets. Oxymorphone ER is an oral extended- release opioid analgesic that was jointly developed with Endo for the treatment of moderate to severe pain in patients requiring continuous, around- the-clock opioid therapy for an extended period of time. ADVERTISEMENT "Oxymorphone ER is our lead development program and we are very excited that the NDA has been submitted to the FDA. We believe oxymorphone ER is an excellent example of how the TIMERx® technology can add value to medicines for both consumers and our partners," said Tod Hamachek, Chairman of the Board and Chief Executive Officer. If approved oxymorphone ER, would give physicians and their patients an important new option for managing chronic pain with twice-daily dosing, and would compete in the growing, approximately $2 billion market for long-acting oral opioids. Mr. Hamachek went on to say, "This has been an exciting year for Penwest. With an agreement to sell our excipient business to Rettenmaier announced in the fourth quarter together with the oxymorphone ER filing, we have made great strides toward executing on our strategy of establishing Penwest as a specialty pharmaceutical business." The filing is based on a development program involving more than 2,400 patients.

To: Biomaven who wrote (7563)	12/20/2002 1:08:54 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

>>Finally an IND from Millenium >> ??? 11/21/02 Millennium Initiates Phase I Clinical Trial of MLN2704 (aka. J591-DM1)in Patients with Metastatic Androgen-Independent Prostate Cancer 12/16/02 Millennium Initiates Phase I Clinical Trial of MLN1202 Erik